On January 10, 2022, PharmaShots has launched a new section in its interview series: Spotlight - Company of the Month
Company of the month is our new exclusive feature under which we are interviewing the key leaders of the start-ups that are providing fierce solutions. We pick one company every month and interview them about…
Shots:
AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B
The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021.
Merck and Pfizer are among the…
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency
Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients
During the month of December, Samsung Bioepis presented five-year follow-up results of…
In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development and a Laboratory Director at Guardant Health & Yoshiaki Nakamura, Staff Physician in the Department of Gastroenterology and Gastrointestinal Oncology shared their views on the benefits of using the Guardant360 liquid biopsy test in P-II (TRIUMPH) study for HER2-driven metastatic colorectal cancer
Shots:
The P-II (TRIUMPH) study evaluates pertuzumab +…
In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & Rheumatology
Shots:
The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
In an interview with PharmaShots, Dr. Amit Etkin, CEO and Founder of Alto Neuroscience shared his views on its clinical stage pipeline in the emerging hot precision psychiatry space. He also put his views on the funding received by the company for the development of its pipeline.
Shots:
Using precision psychiatry, the company’s human data R&D platform identifies brain biomarkers…
In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidence
ERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement &Â to generate the clinical evidence, empower the patients &Â transform their lives by providing better evidence
Clario combines Bioclinica's expertise in imaging,…
In an interview with PharmaShots, Shannon Burke, Synchrony Senior Vice President, and General Manager, Health Systems, share her views on healthcare financing & empowers the patients to pay for their healthcare
Synchrony’s CareCredit card is a comprehensive healthcare financial solution that is designed for health and wellness needs. The CareCredit solution helps health systems, reduce accounts receivable, increase revenue,…
In an interview with PharmaShots, Andrew Hall, CEO at IMV share his views on the data of DPX delivery platform in the bladder and ovarian cancer, presented in two e-posters at the AACR-NCI-EORTC virtual conference
Shots:
The company has reported additional data to support the immunotherapeutic capabilities of its DPX technology. In pre-clinical/clinical data, DPX technology generates peptide-specific, T cell-based immune…
In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the data of the Neural Sleeve gait study for patients with cerebral palsy, MS, stroke, and other neurological disorders
Shots:
Cionic has reported the results from the Neural Sleeve gait study which was conducted in the San Francisco Bay Area. The study showed an…

